NYSE:ABTMedical Equipment
Assessing Abbott Laboratories (ABT) Valuation After Q4 Nutrition Weakness And Ongoing Device Strength
Abbott Laboratories (ABT) is back in focus after its fourth quarter update, where weakness in the Nutrition segment pulled overall sales growth below Wall Street expectations and prompted CEO Robert Ford to begin reshaping that business.
See our latest analysis for Abbott Laboratories.
The recent Q4 earnings miss and softer Nutrition outlook have weighed on sentiment, with a 30 day share price return of an 11.99% decline and a 1 year total shareholder return of a 12.96% decline. The modest 3...